



This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

Claims 1-12(canceled).

13(currently amended). A method of treating or preventing a disease condition caused or exacerbated by an MPV comprising the administration to a mammal in need thereof of an effective amount of a compound ~~capable of facilitating~~ which facilitates the disruption of a chelated metal cation domain of a protein encoded for by an MPV gene ~~to a mammal in need thereof~~, wherein the compound is selected from the group of compounds consisting of general formulae (I) or (II):



wherein


n is selected from 1-5

R<sup>1</sup> - R<sup>4</sup> are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted arylalkyl optionally substituted acyl, optionally

Appl. No. 09/763,616  
Amendment dated: September 11, 2003  
Reply to OA of: March 11, 2003


substituted heterocyclyl, halo alkyl, arylalkyl, carboxy, carboxy ester and carboxamido;  
or

R<sup>1</sup> and R<sup>2</sup> together, and/or R<sup>3</sup> and R<sup>4</sup> together, independently form a group of formula  
(a):



wherein: U is selected from CH<sub>2</sub>, O, NH or S;  
l and n are independently selected from 0 to 6 and m is 0 or 1 when U is CH<sub>2</sub> and m is 1 when U is O, NH or S, such that  
l + m + n is greater than or equal to 2;  
and wherein any one or more (CH<sub>2</sub>) or NH groups may be further optionally substituted or a pharmaceutically acceptable derivative thereof.

14(original). A method according to claim 13 wherein R<sup>1</sup> and R<sup>2</sup> together, and/or R<sup>3</sup> and R<sup>4</sup> together, independently form a group of formula (a):



wherein: U is selected from CH<sub>2</sub>, O, NH or S;  
l and n are independently selected from 0 to 6 and m is 0 or 1 when U is CH<sub>2</sub> and m is 1 when U is O, NH or S, such that  
l + m + n is greater than or equal to 2;  
and wherein any one or more (CH<sub>2</sub>) or NH groups may be further optionally substituted.

15(currently amended). A method according to claim 14 wherein U is CH<sub>2</sub>.

Appl. No. 09/763,616


Amendment dated: September 11, 2003

Reply to OA of: March 11, 2003

16(currently amended). A method according to claim 15 wherein formula (a) is selected from the group consisting one of  $-(CH_2)_{2-}$ ,  $-(CH_2)_3-$ ,  $-(CH_2)_4-$ ,  $-(CH_2)_5-$ ,  $-(CH_2)_6-$  and or  $-(CH_2)_7-$ .

17(original). A method according to claim 14 wherein U is NH, O, or S and m is 1.

18(currently amended). A method according to claim 14 wherein  $R_1$  and  $R_2$ , and/or  $R_3$  and  $R_4$ , together with the nitrogen to which they are attached independently form a group selected from the group consisting of:



which may be optionally substituted at a carbon atom, and/or where U is NH, at the nitrogen atom.

Appl. No. 09/763,616

Amendment dated: September 11, 2003

Reply to OA of: March 11, 2003

19(original). A method according to claim 18 wherein R<sub>1</sub> and R<sub>2</sub>, and/or R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen to which they are attached each independently form an optionally substituted morpholino, thiomorpholino, or piperazino group.

20(currently amended). A method according to claim 14 wherein any -CH<sub>2</sub>- group of formula (a) is optionally substituted by one or more of the groups selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, hydroxy, halo, methoxy, ethoxy, iso-propoxy, acetoxy, optionally substituted benzyl, optionally substituted pyridyl, optionally substituted pyrimidyl and optionally substituted phenyl.

21(currently amended). A method according to claim 13 wherein at least one of R<sup>1</sup> - R<sup>4</sup> is independently selected from the group consisting of: hydrogen, optionally substituted phenyl, optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, and optionally substituted cyclohexyl, formyl, acetyl.

22(currently amended). A method according to claim [[21]] 20 wherein the optional substituent is selected from the ~~groups~~ group consisting of methyl, ethyl, n-propyl, iso-propyl, hydroxy, halo, methoxy, ethoxy, iso-propoxy, acetoxy, and phenyl.


23(currently amended). A method according to claim 13 wherein at least one of R<sup>1</sup>-R<sup>4</sup> ~~is as depicted in any compound in Groups 1 to 6 as defined herein.~~ is selected from the group consisting of:

Appl. No. 09/763,616

Amendment dated: September 8, 2003














Reply to OA of: March 11, 2003

*Sub P1*  
-CH<sub>2</sub>-Ph, -CH<sub>2</sub>-C(O)-O-CH<sub>2</sub>CH<sub>3</sub>, -C(O)H, -CH<sub>2</sub>-CH<sub>3</sub> and







or

R<sup>1</sup> and R<sup>2</sup> together and/or R<sup>3</sup> and R<sup>4</sup> together independently form a group selected from the group consisting of:










Appl. No. 09/763,616  
 Amendment dated: September 8, 2003  
 Reply to OA of: March 11, 2003

Sub  
 10'



Cb



Appl. No. 09/763,616  
Amendment dated: September 11, 2003  
Reply to OA of: March 11, 2003

24(original). A method according to claim 13 wherein n is selected from 1, 2 or 3, preferably 1 or 2.

25(original). A method according to claim 13 wherein the MPV is an HPV.

26(original). A method according to claim 25 wherein the HPV is selected from the group consisting of HPV-1, 2, 3, 4, 6, 11, 16, 18, 27, 31, 33, 35, 45 and 57.

27(original). A method according to claim 26 wherein the HPV is HPV-16.

28(original). A method according to claim 27 wherein the protein is the HPV-16 E6 or E7 oncoprotein.

29(original). A method according to claim 26 wherein the HPV is HPV-18.

30(original). A method according to claim 29 wherein the protein is the HPV-18 E6 or E7 oncoprotein.

31(original). A method according to claim 13 where the chelated metal cation domain is a chelated zinc cation domain.

32(currently amended). A method according to claim 31 wherein the chelated zinc domain is the sequence motif cys-X2-cys-X29-cys-X2-cys (SEQ ID NO:2).

33(original). A method of treating or preventing a disease condition caused or exacerbated by an MPV comprising the administration of an effective amount of a compound as defined in claim 13 to a mammal in need thereof.

Appl. No. 09/763,616

Amendment dated: September 11, 2003

Reply to OA of: March 11, 2003

34(previously presented). A method according to claim 13 wherein the compound is capable of effecting at least 30% zinc release in a TSQ assay and/or inhibits or reduces the binding of an E6 protein to E6AP or E6BP and/or exhibits selective cytotoxicity towards MPV-infected cells.

35(previously presented). A method according to claim 13 wherein the disease or condition is cervical cancer or its HPV associated precursor lesions or any other HPV associated cancers and/or warts.

Claims 36-39(canceled).

40(previously presented). A method of treating or preventing a disease condition caused or exacerbated by an MPV comprising the administration of an effective amount of a compound capable of facilitating the disruption of a chelated metal cation domain of a protein encoded for by an MPV gene to a mammal in need thereof, wherein said compound is a compound identified as a compound useful in the treatment of a disease or condition caused or exacerbated by an MPV by a method which comprises contacting a protein molecule containing a chelated metal cation domain, encoded by an MPV gene, with an effective amount of said compound for a time and under conditions sufficient to facilitate disruption of the chelated metal cation domain and directly or indirectly determining the amount of chelated metal cation released wherein the amount of chelated metal cation released is indicative of the disruption of the chelated metal cation domain.